Okan Safak
The COVID-19 pandemic is expected to have long-lasting effects on cancer clinical trials, which could speed up patient access to novel medicines. With the help of recent data on global clinical trials gathered by IQVIA, an international panel of oncology experts explores the pandemic's long-term effects on cancer clinical trials and suggests solutions for clinical trial stakeholders. The epidemic has brought to light the need for novel trial designs that speed up research, reduce risks and burdens for patients, and optimize the goals and endpoints of clinical trials while minimizing testing.